Drug
Acapatamab
Acapatamab: highest development phase Phase 1/2, developed by Amgen. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Amgen
Trials
| Drug | Phase | Indication |
|---|---|---|
| Acapatamab NCT04631601 | Phase 1/2 | Metastatic Castration-resistant Prostate Cancer |
| acapatamab NCT03792841 | Phase 1 | Metastatic Castration-resistant Prostate Cancer |
Latest
No recent events.
Follow Acapatamab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.